Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

MOUNTAIN VIEW, Calif., April 12, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new data from two safety studies of LEVADEX® orally inhaled migraine drug.  The data will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011.  LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.

Findings to be presented at 2:00 p.m. HAST today in the poster titled "An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45) in Smoking and Non-Smoking Adult Volunteers," show that:

  • LEVADEX exposure was not higher in smokers, potentially due to reduced pulmonary absorption
  • LEVADEX was quickly absorbed into the bloodstream of both smokers and non-smokers, as evidenced by a median Tmax of 4.98 and 7.02 minutes respectively
  • The mean half-life for LEVADEX was similar for smokers (16.1 hours) and non-smokers (14.5 hours) and was similar to IV DHE administration (13.3 hours for smokers and 12.4 hours for non-smokers)
  • Tolerability of LEVADEX was similar in smokers and non-smokers

  • Findings in a separate safety study to be presented at 2:00 p.m.  HAST today in the poster titled "A Randomized, Double-Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic Pressure," show that:

  • Neither LEVADEX, IV DHE nor placebo produced clinically significant changes in pulmonary arterial systolic pressure (PASP) or other cardiac functions; however a statistically higher elevation of PASP was found following IV DHE treatment compared to the LEVADEX and placebo treatment  
  • There was no statistical difference in PASP between the LEVADEX and placebo groups over two hours
  • No significant electrocardiogram (ECG) changes were observed
  • Adverse events were more frequent in the IV DHE group than in the LEVADEX or placebo groups

  • The three additional LEVADEX related presentations are:
    Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical
    Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HAST
    Presentation Info: April 12, 2011 at 3:45 p.m. HAST
    Presentation #: 004

    This presentation has been selected by the Scientific Program Subcommittee to be in the top five percent of the American Academy of Neurology presentations and, as such, LEVADEX will be highlighted by the Subcommittee during the Scientific Program Highlights Plenary Session on Friday, April 15, 5:15 – 6:15 p.m.

    The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic Activity
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 272

    Migraine Recurrence Rates: Case for Standardization of the Definition
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 285

    About LEVADEX® LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

  • The most common adverse event reported was medication aftertaste at six percent versus two percent for placebo.  The next most common adverse event was nausea at five percent compared with two percent for placebo.  There were no decreases in lung function, as measured by spirometry, between the active and placebo groups. 

    About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).  According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days.  On average, migraine sufferers experience three migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.  The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

    About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology.  The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine.  The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.  Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com

    Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate.  Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application and the regulatory process to have the company's LEVADEX product candidate approved for commercial use.  The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release.  MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.  Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2010, available at http://edgar.sec.gov. CONTACT:Nicole Foderaro

    Lisa BorlandWCG

    MAP Pharmaceuticals, Inc.(415) 946-1058

    650-386-3122nfoderaro@wcgworld.com
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
    (Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... Jones Industrial Average edged 0.36% higher, to finish at 19,191.93; ... were broad based as six out of nine sectors ended ... on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... INC Research Holdings Inc. (NASDAQ: INCR ), and ...
    (Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
    (Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
    (Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Yisrayl Hawkins, ... delves into how this current generation fits into Bible Prophecy. Yisrayl says this generation, ... facts pointing to this conclusion, showing how the details line up exactly with Bible ...
    (Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., ... $6.0 million in an initial round of funding. The round was led by ... caregivers can receive far better care through the application of the best technologies ...
    (Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, ... connected applications, was named the best Sales Team of 2016 as part of ... made today by the Software & Information Industry Association (SIIA), the principal trade ...
    Breaking Medicine News(10 mins):